Journal article
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, P McGale, H Pan, C Taylor, W Barlow, J Bliss, P Bruzzi, D Cameron, G Fountzilas, S Loibl, J Mackey, M Martin, L Del Mastro, V Möbus Show all
Lancet | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Background: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. Methods: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank a..
View full abstractGrants
Awarded by National Center for Advancing Translational Sciences
Funding Acknowledgements
Cancer Research UK, Medical Research Council.